Split History
ETFs Holding ALKS »    ALKS Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA (aripiprazole lauroxil), an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension), a once-monthly, non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification; INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and RISPERDAL CONSTA; AMPYRA (dalfampridine)/FAMPYRA (fampridine), a treatment to improve walking in adults with multiple sclerosis who have walking disability; and BYDUREON and BYDUREON BCise, a treatment of type 2 diabetes. According to our ALKS split history records, Alkermes has had 1 split.
ALKS split history picture
Alkermes (ALKS) has 1 split in our ALKS split history database. The split for ALKS took place on May 15, 2000. This was a 2 for 1 split, meaning for each share of ALKS owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Alkermes splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the ALKS split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alkermes shares, starting with a $10,000 purchase of ALKS, presented on a split-history-adjusted basis factoring in the complete ALKS split history. ALKS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/20/2009
End date: 02/19/2019
Start price/share: $11.16
End price/share: $34.09
Dividends collected/share: $0.00
Total return: 205.47%
Average Annual Total Return: 11.81%
Starting investment: $10,000.00
Ending investment: $30,544.94
Years: 10.00
Date Ratio
05/15/20002 for 1
ALKS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ALPN Split History
ALQA Split History
ALR Split History
ALT Split History
ALXA Split History
ALXN Split History
AMDA Split History
AMED Split History
AMGN Split History
AMN Split History

Also explore: ALKS shares outstanding history

Trovagene, Inc. (TROV)
Celldex Therapeutics, Inc. (CLDX)
Pulmatrix, Inc. (PULM)
Titan Pharmaceuticals, Inc. (TTNP)
Bio-Path Holdings, Inc. (BPTH)
Enghouse Systems Limited (ENGH.CA)
Camber Energy, Inc. (CEI)
Diffusion Pharmaceuticals Inc. (DFFN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ALKS Insider Buying

ALKS Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.